Blood compatibility of enveloped viruses

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 4, 2010, Pages 412-420

  Kueberuwa, G ^a   Cawood, R ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; MANNAN BINDING LECTIN; NEUTRALIZING ANTIBODY; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS ANTIBODY; COMPLEMENT;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BLOOD COMPATIBILITY; BLOOD COMPONENT; COMPLEMENT ACTIVATION; DRUG POTENTIATION; ERYTHROCYTE ADHESIVENESS; EXOSOME; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OPSONIZATION; PLASMA CLEARANCE; PRIMARY TUMOR; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ANIMAL; IMMUNOLOGY; MATERIALS TESTING; PROCEDURES; TRENDS; VIRUS;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; HUMANS; MATERIALS TESTING; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUSES;

EID: 77955345961     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Byrnes AP, Griffin DE: Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J Virol (2000) 74(2):644-651.
2. Fisher KD, Seymour LW: HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev 62(2):240-245.
3. Havlir DV, Eastman S, Gamst A, Richman DD: Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 70(11):7894-7899.
4. da Silva LC, Nova ML, Ono-Nita SK, Pinho JR, Sitnik R, Santos VA, Carrilho FJ: Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med Trop Sao Paulo (2009) 51(5): 261-268.
5. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett (2007) 254(2):178-216.
6. Graat HC, van Beusechem VW, Schagen FH, Witlox MA, Kleinerman ES, Helder MN, Gerritsen WR, Kaspers GJ, Wuisman PI: Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases. Mol Cancer (2008) 7:9.
7. Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K, Tanzawa H: Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncol (2009) 45(12):1021-1027.
8. Blue CE, Spiller OB, Blackbourn DJ: The relevance of complement to virus biology. Virology (2004) 319(2):176-184.
9. Mochizuki Y, de ming T, Hayashi T, Itoh M, Hotta H, Homma M: Protection of mice against Sendai virus pneumonia by non-neutralizing anti-F monoclonal antibodies. Microbiol Immunol (1990) 34(2):171-183.
10. Spear GT, Takefman DM, Sullivan BL, Landay AL, Jennings MB, Carlson JR: Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human-immunodeficiency-virus and simian immunodeficiency virus. Virology (1993) 195(2):475-480.
11. Vasantha S, Coelingh KL, Murphy BR, Dourmashkin RR, Hammer CH,Frank MM, Fries LF: Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology (1988) 167(2): 433-441.
12. Cornelissen E, Dewerchin HL, Van Hamme E, Nauwynck HJ: Absence of antibody-dependent, complement-mediated lysis of feline infectious peritonitis virus-infected cells. Virus Res (2009) 144(1-2):285-289.
13. Stoiber H, Speth C, Dierich MP: Role of complement in the control of HIV dynamics and pathogenesis. Vaccine (2003) 21:S77-S82. (Pubitemid 36588652)
14. Spear GT, Sullivan BL, Landay AL, Lint TF: Neutralization of human-immunodeficiency-virus type-1 by complement occurs by viral lysis. J Virol (1990) 64(12):5869-5873.
15. Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, Spear GT: Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol (1996) 157(4):1791-1798.
16. Spiller OB, Morgan PB: Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts. J Infect Dis (1998) 178(6):1597-1603.
17. Cooper NR, Jensen FC, Welsh RM, Oldstone MBA: Lysis of RNA tumor-viruses by human-serum-Direct antibodyindependent triggering of classical complement pathway. J Exp Med (1976) 144(4):970-984.
18. Solder BM, Schulz TF, Hengster P, Lower J, Larcher C, Bitterlich G, Kurth R, Wachter H, Dierich MP: HIV and HIV-infected cells differentially activate the human-complement system independent of antibody. Immunol Lett (1989) 22(2):135-145.
19. Ikeda F, Haraguchi Y, Jinno A, Iino Y, Morishita Y, Shiraki H, Hoshino H: Human complement component C1q inhibits the infectivity of cell-free HTLV-I. J Immunol (1998) 161(10): 5712-5719.
20. Moulton EA, Atkinson JP, Buller RML: Surviving mousepox infection requires the complement system. PLoS Pathog (2008) 4(12):e1000249.
21. Benhnia M, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2009) 83(3):1201-1215.
22. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC: Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS (1993) 7(10):1307-1313.
23. Hartshorn KL, Sastry K, White MR, Anders EM, Super M, Ezekowitz RA, Tauber AI: Human mannose-binding protein functions as an opsonin for influenza A viruses. J Clin Invest (1993) 91(4):1414-1420.
24. Thielens NM, Tacnet-Delorme P, Arlaud GJ: Interaction of C1q and mannan-binding lectin with viruses. Immunobiology (2002) 205(4-5):563-574.
25. Wang FS: Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol (2003) 9(4):641-644.
26. Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP. Mannan binding lectin and viral hepatitis. Immunol Lett (2007) 108(1):34-44.
27. Sasaki K, Tsutsumi A, Wakamiya N, Ohtani K, Suzuki Y, Watanabe Y, Nakayama N, Koike T: Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol (2000) 35(9):960-965.
28. Davies KA: Complement. Baillieres Clin Haematol (1991) 4(4): 927-955.
29. Hirsch RL, Winkelstein JA, Griffin DE: The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus. J Immunol (1980) 124(5):2507-2510.
30. Devaux P, Christiansen D, Plumet S, Gerlier D: Cell surface activation of the alternative complement pathway by the fusion protein of measles virus. J Gen Virol (2004) 85(Pt 6): 1665-1673.
31. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM: Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med Genomics (2009) 2:51.
32. Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang XY, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, Garcia-Sastre A: Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA (2002) 99(16):10736-10741.
33. Favoreel HW, Van de Walle GR, Nauwynck HJ, Pensaert MB: Virus complement evasion strategies. J Gen Virol (2003) 84(Pt 1):1-15.
34. Dowler KW, Veltri RW: In vitro neutralization of HSV-2: Inhibition by binding of normal IgG and purified Fc to virion Fc receptor (FcR). J Med Virol (1984) 13(3):251-259.
35. Frank I, Friedman HM: A novel function of the herpes simplex virus type 1 Fc receptor: Participation in bipolar bridging of antiviral immunoglobulin G. J Virol (1989) 63(11):4479-4488.
36. Banki Z, Stoiber H, Dierich MP: HIV and human complement: Inefficient virolysis and effective adherence. Immunol Lett (2005) 97(2):209-214.
37. Schols D, Pauwels R, Desmyter J, Declercq E: Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology (1992) 189(1):374-376.
38. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK: Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 68(12):8001-8007.
39. Clayton A, Harris CL, Court J, Mason MD, Morgan BP: Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol (2003) 33(2):522-531.
40. Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH: Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 17(2):73-79.
41. Gras GS, Dormont D: Antibody-dependent and antibodyindependent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol (1991) 65(1):541-545.
42. Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol (2002) 169(6):3301-3306.
43. Klasse PJ, Sattentau QJ: Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol (2002) 83(Pt 9):2091-2108.
44. Maeda H, Bharate GY, Daruwalla J: Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm (2009) 71(3):409-419.
45. Gobet R, Cerny A, Ruedi E, Hengartner H, Zinkernagel RM: The role of antibodies in natural and acquired-resistance of mice to vesicular stomatitis-virus. Exp Cell Biol (1988) 56(4):175-180.
46. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, Zinkernagel RM: Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 286(5447):2156-2159.
47. Matter MS, Ochsenbein AF: Natural antibodies target virusantibody complexes to organized lymphoid tissue. Autoimmun Rev (2008) 7(6):480-486.
48. Beck Z, Prohászka Z, Fst G: Traitors of the immune system-enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development. Vaccine (2008) 26(24):3078-3085.
49. Rodrigo W, Jin X, Blackley SD, Rose RC, Schlesinger JJ: Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signalingincompetent human Fcγ RIA (CD64) or FcγRIIA (CD32). J Virol (2006) 80(20):10128-10138.
50. Olsen CW, Corapi WV, Ngichabe CK, Baines JD, Scott FW: Monoclonal-antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol (1992) 66(2):956-965.
51. Huisman W, Martina BEE, Rimmelzwaan GF, Gruters RA, Osterhaus A: Vaccine-induced enhancement of viral infections. Vaccine (2009) 27(4):505-512.
52. Parato KA, Senger D, Forsyth PAJ, Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 5(12):965-976.
53. Zhu H, Su Y, Zhou S, Xiao W, Ling W, Hu B, Liu Y, Qi Y: Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice. Cancer Biol Ther (2007) 6(5):724-731.
54. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, et al.: Phase II clinical trial of a granulocytemacrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 27(34):5763-5771.
55. Parato KA, Senger D, Forsyth PAJ, Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 5(12):965-976.
56. Nelson RA: The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science (1953) 118(3077):733-737.
57. Schifferli JA, Taylor RP: Physiological and pathological aspects of circulating immune-complexes. Kidney Int (1989) 35(4): 993-1003.
58. Villiers MB, Marche PN, Villiers CL: Improvement of long-lasting response and antibody affinity by the complexation of antigen with complement C3b. Int Immunol (2003) 15(1):91-95.
59. Madi N, Paccaud JP, Steiger G, Schifferli JA: Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1). Clin Exp Immunol (1991) 84(1):9-15.
60. Helmy KY, Katschke KJ, Gorgani NN, Elliott JM, Diehl L, Scales SJ, Ghilardi N, Campagne MV: CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 124(5):915-927.
61. Yan J, Vetvicka V, Xia Y, Hanikyrova M, Mayadas TN, Ross GD: Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble β-glucan. Immunopharmacology (2000) 46(1):39-54.
62. Roozendaal R, Carroll MC: Emerging patterns in complementmediated pathogen recognition. Cell (2006) 125(1):29-32.
63. Colten HR, Rosen FS: Complement deficiencies. Annu Rev Immunol (1992) 10:809-834.
64. Zahn A, Jennings N, Ouwehand WH, Allain JP: Hepatitis C virus interacts with human platelet glycoprotein VI. J Gen Virol (2006) 87(Pt 8):2243-2251.
65. Bik T, Sarov I, Livne A: Interaction between vaccinia virus and human-blood platelets. Blood (1982) 59(3):482-487.
66. Lee TH, Stromberg RR, Heitman JW, Sawyer L, Hanson CV, Busch MP: Distribution of HIV type 1 (HIV-1) in blood components: Detection and significance of high levels of HIV-1 associated with platelets. Transfusion (1998) 38(6): 580-588.
67. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER: β3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA (1998) 95(12):7074-7079.
68. Wang SG, He RT, Patarapotikul J, Innis BL, Anderson R: Antibody-enhanced binding of dengue-2 virus to human platelets. Virology (1995) 213(1):254-257.
69. Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 81(Pt 11): 2605-2609.
70. Martinet O, Schreyer N, Reis ED, Joseph JM: Encapsulation of packaging cell line results in successful retroviral-mediated transfer of a suicide gene in vivo in an experimental model of glioblastoma. Eur J Surgical Oncol (2003) 29(4):351-357.
71. Saller RM, Indraccolo S, Coppola V, Esposito G, Stange J, Mitzner S, Amadori A, Salmons B, Gunzburg WH: Encapsulated cells producing retroviral vectors for in vivo gene transfer. J Gene Med (2002) 4(2):150-160.
72. Dvir-Ginzberg M, Konson A, Cohen S, Agbaria R: Entrapment of retroviral vector producer cells in three-dimensional alginate scaffolds for potential use in cancer gene therapy. J Biomed Mater Res Part B (2007) 80B(1):59-66.
73. Power AT, Bell JC: Taming the trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther (2008) 15(10):772-779.
74. Power AT, Wang JH, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PAJ, Atkins H, Bell JC: Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 15(1):123-130.
75. Raykov Z, Balboni G, Aprahamian M, Rommelaere J: Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer (2004) 109(5):742-749.
76. Liu TC, Kirn D: Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Ther (2008) 15(12):877-884.
77. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT: Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 182(2):501-509.
78. Krauss O, Hollinshead R, Hollinshead M, Smith GL: An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol (2002) 83(Pt 10):2347-2359.
79. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol (1995) 155(9):4376-4381.
80. Metzner C, Mostegl MM, Gnzburg WH, Salmons B, Dangerfield JA: Association of glycosylphosphatidylinositol-anchored protein with retroviral particles. FASEB J (2008) 22(8):2734-2739.
81. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan XG, Lu YH, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, et al.: Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 67(19):9398-9406.
82. Haisma HJ, Kamps J, Kamps GK, Plantinga JA, Rots MG, Bellu AR: Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol (2008) 89(Pt 5):1097-1105.